CONFIDENTIAL ------------License Agreement • July 21st, 1999 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations • California
EXHIBIT 10.1 BIOMARIN PHARMACEUTICAL INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (the "AGREEMENT") is effective as of 1998, by and between Biomarin Pharmaceutical Inc., a Delaware corporation (the "COMPANY"), and ___________ (the...Indemnification Agreement • May 4th, 1999 • Biomarin Pharmaceutical Inc • Delaware
EXHIBIT 10.30 OPERATING AGREEMENTOperating Agreement • July 6th, 1999 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations • Delaware
AMENDMENT III TO LEASE AGREEMENT DATED MAY 18, 1998 BY AND BETWEEN PIAZZA TRADING & COMPANY, LTD., LANDLORD AND BIOMARIN PHARMACEUTICAL, INC., TENANT DATED OCTOBER 3, 2000Lease Agreement • April 1st, 2002 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations
UNDERWRITING AGREEMENT UNDERWRITING AGREEMENTUnderwriting Agreement • December 4th, 2001 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations • New York
EXHIBIT 1.1 BIOMARIN PHARMACEUTICAL INC. Common Stock (par value $0.001 per share) U.S. Underwriting AgreementBiomarin Pharmaceutical Inc • July 21st, 1999 • Pharmaceutical preparations • New York
EXHIBIT 10.26 SUBSCRIPTION AGREEMENT TO: BIOMARIN PHARMACEUTICAL INC. RE: SUBSCRIPTION FOR AND PURCHASE OF SHARES OF COMMON STOCK 1. SUBSCRIPTION ------------ Genzyme Corporation (the "PURCHASER") hereby irrevocably subscribes for and agrees to...Subscription Agreement • May 4th, 1999 • Biomarin Pharmaceutical Inc • California
371 BEL MARIN KEYS BOULEVARD LEASE AGREEMENTLease Agreement • May 4th, 1999 • Biomarin Pharmaceutical Inc • California
BIOMARIN PHARMACEUTICAL INC. (a Delaware corporation)Underwriting Agreement • August 11th, 2017 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations • New York
BioMarin Pharmaceutical Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Merrill Lynch, Pierce, Fenner & Smith Incorporated, Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Merrill Lynch, Pierce, Fenner & Smith Incorporated, Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of $450,000,000 aggregate principal amount of the Company’s 0.599% Senior Subordinated Convertible Notes due 2024 (the “Notes”) and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to pu
RECITALS:Registration Rights Agreement • May 4th, 1999 • Biomarin Pharmaceutical Inc • California
Exhibit 1.2 COMMON STOCK PURCHASE AGREEMENT Dated as of August 15, 2001 by and between BIOMARIN PHARMACEUTICAL INC.Common Stock Purchase Agreement • August 16th, 2001 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations • New York
2 - SECTION 3. Conditions to Effectiveness. The effectiveness of the amendments set forth in Section 2 hereof are subject solely to satisfaction of the following conditions precedent (the date of such satisfaction being the “Amendment Effective...Credit Agreement • July 30th, 2021 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations • New York
RECITALSLease • April 1st, 2002 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations
EXHIBIT 2.1 THIS SHARE EXCHANGE AGREEMENT made as of the 15th day of September, 1998. B E T W E E N: GLYKO BIOMEDICAL LTD., a corporation incorporated under the laws of Canada, (hereinafter called the "Vendor")Share Exchange Agreement • May 4th, 1999 • Biomarin Pharmaceutical Inc
Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the "Agreement"), made as of October 31, 2000 (the "Effective Date") by and between BioMarin Pharmaceutical Inc., a Delaware corporation with its principal executive offices located at 371...Employment Agreement • January 11th, 2001 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations • California
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT is entered into as of May 16, 2001 among BioMarin Pharmaceutical Inc., a Delaware corporation (the "Company"), and the other Persons listed on Annex A hereto (sometimes...Securities Purchase Agreement • May 18th, 2001 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations • Delaware
EXHIBIT 10.26 SUBSCRIPTION AGREEMENT TO: BIOMARIN PHARMACEUTICAL INC. RE: SUBSCRIPTION FOR AND PURCHASE OF SHARES OF COMMON STOCK 1. SUBSCRIPTION ------------ Genzyme Corporation (the "PURCHASER") hereby irrevocably subscribes for and agrees to...Subscription Agreement • June 14th, 1999 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations • California
EXHIBIT 10.5 BIOMARIN PHARMACEUTICAL INC. AMENDED AND RESTATED FOUNDER'S STOCK PURCHASE AGREEMENT THIS AGREEMENT (the "Agreement") is made between John Klock (the "Purchaser") and BIOMARIN PHARMACEUTICAL INC. (the "Company") as of October 1, 1997....Security Agreement • May 4th, 1999 • Biomarin Pharmaceutical Inc • California
EXHIBIT 2.1 THIS SHARE EXCHANGE AGREEMENT made as of the 15th day of September, 1998. B E T W E E N: GLYKO BIOMEDICAL LTD., a corporation incorporated under the laws of Canada, (hereinafter called the "Vendor")Registration Rights Agreement • June 14th, 1999 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations • California
EXHIBIT 10.20 46 GALLI DRIVE, NOVATO, CALIFORNIA STANDARD NNN LEASE--MULTI- TENANT PROPERTY WITNESSETHBiomarin Pharmaceutical Inc • May 4th, 1999
EXHIBIT 10.25 PURCHASE AGREEMENTPurchase Agreement • May 4th, 1999 • Biomarin Pharmaceutical Inc • Massachusetts
OPTION AGREEMENT ----------------Option Agreement • June 14th, 1999 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations • California
RECITALSEmployment Agreement • May 4th, 1999 • Biomarin Pharmaceutical Inc
EXHIBIT 10.24 CONFIDENTIAL ------------ [* * *]: CONFIDENTIAL TREATMENT REQUESTED FOR PORTIONS OF THIS EXHIBIT COLLABORATION AGREEMENTCollaboration Agreement • July 21st, 1999 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations • Massachusetts
ANNEX A-1Amending Agreement • August 26th, 2002 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations • Delaware
BIOMARIN PHARMACEUTICAL INC. (a Delaware corporation)Purchase Agreement • April 23rd, 2007 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations • New York
BioMarin Pharmaceutical Inc., a Delaware corporation (the “Company”), confirms its agreement with Merrill Lynch & Co., Merrill Lynch, Pierce, Fenner & Smith Incorporated (“Merrill Lynch” or the “Underwriter”), with respect to (i) the sale by the Company and the purchase by the Underwriter of $282,500,000 aggregate principal amount of the Company’s 1.875% Senior Subordinated Convertible Notes due 2017 (the “Notes”), and (ii) the grant by the Company to the Underwriter of the option described in Section 2(b) hereof to purchase all or any part of an additional $42,375,000 aggregate principal amount of the Notes to cover overallotments, if any. The aforesaid $282,500,000 aggregate principal amount of the Notes (the “Initial Securities”) to be purchased by the Underwriter and all or any part of the $42,375,000 aggregate principal amount of the Notes subject to the option described in Section 2(b) hereof (the “Option Securities”) are hereinafter called, collectively, the “Securities.” The Se
JOINT FILING AGREEMENT Exhibit 1.1 ---------- JOINT FILING AGREEMENTJoint Filing Agreement • August 5th, 2004 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations
The undersigned hereby agree that the Statement on this Schedule 13G, dated June 1, 2004, (the "Schedule 13G"), with respect to the Common Stock, $0.001 par value per share, of Biomarin Pharmaceutical Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
RECITALSEmployment Agreement • June 14th, 1999 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations
EXHIBIT 10.27 BIOMARIN PHARMACEUTICAL INC. CONVERTIBLE NOTE PURCHASE AGREEMENT This Convertible Note Purchase Agreement (the "AGREEMENT") is made as of April 12, 1999, by and between BioMarin Pharmaceutical Inc., a Delaware corporation (the...Convertible Note Purchase Agreement • June 14th, 1999 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations • California
EXHIBIT 4.5 FORM OF AGREEMENT BETWEEN GLYKO BIOMEDICAL OPTIONEES AND BIOMARIN PHARMACEUTICAL INC.Biomarin Pharmaceutical Inc • August 9th, 1999 • Pharmaceutical preparations
As you know, Glyko Biomedical Ltd. ("Glyko Biomedical") intends to enter into an Agreement (the "Agreement") with BioMarin Pharmaceutical Inc. ("BioMarin"), pursuant to which BioMarin will purchase all of the outstanding capital stock of Glyko, Inc. from Glyko Biomedical (the "Acquisition").
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 12th, 2003 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations • New York
THIS REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made and entered into as of June 23, 2003, by and between BioMarin Pharmaceutical Inc., a Delaware corporation (the “Company”), and UBS Securities LLC and CIBC World Markets Corp. (collectively, the “Initial Purchasers”), for whom UBS Securities LLC is acting as representative, pursuant to that certain Purchase Agreement, dated as of June 18, 2003 (the “Purchase Agreement”) between the Company and the Initial Purchasers.
EMPLOYMENT AGREEMENTEmployment Agreement • September 5th, 2012 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations • California
THIS EMPLOYMENT AGREEMENT (“Agreement”) made effective as of September 5, 2012 (“Effective Date”) by and between BioMarin Pharmaceutical Inc., a Delaware corporation (the “Company”) and Jeffrey R. Ajer (“Employee”).
RECITALSAssignment and Assumption of Agreement • April 1st, 2002 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations • California
BIOMARIN PHARMACEUTICAL INC. a Delaware corporation and MELLON INVESTOR SERVICES LLC a New Jersey limited liability company as Rights Agent AMENDED AND RESTATED RIGHTS AGREEMENT Dated as of February 27, 2009Rights Agreement • February 27th, 2009 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations • New York
Amended and Restated Rights Agreement (the “Agreement”), dated as of February 27, 2009, between BioMarin Pharmaceutical Inc., a Delaware corporation (the “Company”) and Mellon Investor Services LLC, a New Jersey limited liability company as Rights Agent (the “Rights Agent”).
EXHIBIT 10.21 [LOGO OF AMERICAN INDUSTRIAL REAL ESTATE ASSOCIATION APPEARS HERE] STANDARD INDUSTRIAL/COMMERCIAL SINGLE-TENANT LEASE- GROSS (DO NOT USE THIS FORM FOR MULTI-TENANT BUILDINGS) 1. BASIC PROVISIONS ("BASIC PROVISIONS") 1.1 PARTIES: This...Biomarin Pharmaceutical Inc • May 4th, 1999
